MR-guided HIFU: Increasing therapeutic options for patients

TOHETI funded access to a £450K MR-guided High Intensity Focussed Ultrasound (HIFU) system

High Intensity Focussed Ultrasound (HIFU) uses focused ultrasound waves to destroy pathological tissue by rapid heating. The efficacy of such treatments is well proven; they are less invasive and outcomes are often much better than surgery.

Advantages:

  • Minimally invasive.
  • MR-guided three-dimensional visualization for precise treatment planning.
  • Real-time monitoring of thermal damage in the target zone with MR thermometry.
  • Continuous temperature mapping of treated tissue, and immediate assessment of therapy.

MR-HIFU utilises high quality MR imaging to plan, deliver and monitor non invasive ultrasound therapy. The new MR-HIFU system will allow clinicians to:

  • investigate new clinical applications for MR-HIFU.
  • provide options for patients where other treatments have been excluded or failed.

Currently MRgHIFU is CE marked for treatment of uterine fibroids and palliation of pain from bone metastases. Our goal is to expand the scope of indications for MRgHIFU, beyond these, to include other musculo-skeletal conditions, breast cancer, primary renal tumours, neurolysis and targeted drug delivery. A non-randomised feasibility study investigating the efficacy of Magnetic Resonance guided High Intensity Focused Ultrasound (MRgHIFU) as a palliative treatment for metastatic bone pain is currently recruiting patients who are no longer under any treatment for bone metastasis. The study has recruited 3 patients so far and aims to recruit 10patients each in control and treatment arm. HIFU treatment is offered as multidisciplinary approach involving several experts : consultants in interventional radiology (GSTT), Prof Afsin Gangi, visiting consultant and leading expert in MRgHIFU treatment, medical physicists, consultant anesthetist and MRI team. Procedure is done under sedation and patients are admitted for overnight observation.

Our goal is to expand the scope of indications for MRgHIFU, beyond these, to include other musculo-skeletal conditions, breast cancer, primary renal tumours, neurolysis and targeted drug delivery.

HIFU scan